

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A pharmaceutical composition comprising:

an effective amount of amlodipine;

an effective amount of hydroxylated atorvastatin metabolite; and

a pharmaceutically acceptable carrier or diluent,

wherein the effective amounts of amlodipine and hydroxylated atorvastatin metabolite ~~coordinated~~
~~to substantially~~ synergistically inhibit lipid peroxidation in human low density lipoprotein or lipid
membrane to achieve a therapeutic effect.

Claim 2 (currently amended): The pharmaceutical composition of claim 1, wherein the amlodipine is
provided is a therapeutically ~~as an~~ effective derivative of amlodipine.

Claim 3 (currently amended): The pharmaceutical composition of claim 2, wherein the
therapeutically effective derivative of amlodipine comprises amlodipine besylate.

Claim 4 (currently amended): The pharmaceutical composition of claim 1, wherein said amounts of
amlodipine and hydroxylated atorvastatin metabolite are coordinated to synergistically inhibit lipid
peroxidation to the extent necessary to achieve the therapeutic effect of reducing the risk of arterial
and related heart disease.

Claim 5 (currently amended): The pharmaceutical composition of claim 4, wherein said arterial and
related heart disease is selected from the group consisting of hypertension, hyperlipidemia,
atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart
failure, stroke, and angina pectoris.

Claim 6 (currently amended): The pharmaceutical composition of claim 1, wherein said amounts of
amlodipine and hydroxylated atorvastatin metabolite are coordinated to synergistically inhibit lipid
peroxidation ~~to the extent necessary to achieve the therapeutic effect of lowering blood pressure.~~

Claims 7- 28 (canceled)

Claims 29-56 (withdrawn)

Claim 57 (currently amended); A pharmaceutical composition comprising:

an amount of amlodipine;

an amount of hydroxylated atorvastatin metabolite; and

a pharmaceutically effective carriers or diluents.

Claim 58 (currently amended): The pharmaceutical composition of claim 57, wherein ~~where~~ the amlodipine comprises a therapeutically effective derivative of amlodipine.

Claim 59 (currently amended): The pharmaceutical composition of claim ~~57~~58, wherein the therapeutically effective derivative of amlodipine comprises amlodipine besylate.

Claims 60-62 (withdrawn)

Claim 63 (currently amended): A pharmaceutical composition comprising:

an effective amount of amlodipine;

an effective amount of hydroxylated atorvastatin metabolite; and

a pharmaceutically acceptable carrier or diluent;

wherein said effective amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that ~~an a synergistic~~ antioxidant effect is achieved ~~by the combined amounts which is greater than the antioxidant effect of either said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite separately.~~

Claim 64 (currently amended): A pharmaceutical composition comprising:

an effective amount of amlodipine;

an effective amount of hydroxylated atorvastatin metabolite; and

a pharmaceutically acceptable carrier or diluent;

wherein said effective amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that ~~the a synergistic~~ inhibition of lipid peroxidation is achieved ~~by the combined amounts is greater than the inhibition of lipid peroxidation achieved by either said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite separately.~~

Claim 65 (currently amended): The pharmaceutical composition of claim 64, wherein said selection is further coordinated for achieving ~~an a synergistic~~ antioxidant effect, ~~which effect is greater than~~

Appl. No. 10/033,149

Amdt. Date July 12, 2004

Reply to Office Action of January 29, 2004 (in response to Advisory Action of June 3, 2004)

Attorney Docket No. 2189-1 P01CIP

~~the antioxidant effect achieved by said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite independently.~~

Claim 66 (new): The pharmaceutical composition of claim 63, wherein said composition is used to treat atherosclerosis.

Claim 67 (new): The pharmaceuticals composition of claim 66, wherein said atherosclerosis involves diseases selected from the group consisting of myocardial infarction, stroke, transient ischemic attack, coronary heart disease and a combination thereof.

Claim 68 (new): The pharmaceutical composition of claim 63, further comprising an endogenous and/or exogenous antioxidant.